Search for dissertations about: "UCHL5"

Showing result 1 - 5 of 6 swedish dissertations containing the word UCHL5.

  2. 1. Potential New Drugs in Lymphoma

    Author : Maryam Delforoush; Gunilla Enblad; Mattias Berglund; Christina Drott; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; lymphoma; diffuse large B-cell lymphoma; DLBCL; picropodophyllin; PPP; J1; melflufen; prodrug; cancer therapeutics; alkylating agents; b-AP15; proteasome inhibitors; DUB inhibition; UCHL5; USP14;

    Abstract : Lymphomas are malignant tumours arising from cells in the lymphatic system. They are classified as B-cell lymphomas, T-cell lymphomas and Hodgkin lymphoma (HL). Of the B-cell lymphomas, one of the most common is diffuse large B-cell lymphoma (DLBCL). READ MORE

  4. 2. Mechanistic studies of a novel inhibitor of the ubiquitin-proteasome system

    Author : Ellin-Kristina Hillert; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : The ubiquitin-proteasome system (UPS) not only maintains cellular proteostasis, but plays an essential role in multiple vital cellular processes, including survival and growth. Proteasomal inhibitors, such as bortezomib, have been shown to have effective anti-cancer properties, verifying the UPS as a viable drug target in cancer treatment. READ MORE

  5. 3. Studies of overcoming acquired resistance : molecular mechanisms and development of novel drugs

    Author : Xin Wang; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : Chemotherapeutic agents have become widely applied for treatment of various types of malignancies. Drug resistance unfortunately remains as a major obstacle for the effectiveness of chemotherapy. Cancer drug resistance includes two broad categories: intrinsic and acquired. READ MORE

  6. 4. Identification and characterization of a proteasome deubiquitinase inhibitor

    Author : Slavica Brnjic; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : The 26S proteasome has emerged as an attractive therapeutic target in the treatment of cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has clinically validated the 26S proteasome as a therapeutic target in oncology. READ MORE

  7. 5. Inhibition of 19S proteasome deubiquitinases as a promising strategy in cancer therapy

    Author : Magdalena Mazurkiewicz; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : The ubiquitin proteasome system (UPS) is the main degradation system in the eukaryotic cell and it is involved in the regulation of many crucial cellular pathways; such as signal transduction, proliferation, DNA repair, cell death, and cell cycle regulation. In comparison to cells in healthy tissues, cancer cells proliferate faster and have increased protein synthesis rate; therefore in order to preserve cellular fitness they are more dependent on UPS than normal cells. READ MORE